DiaMedica Therapeutics (DMAC) investor relations material

Key program updates and clinical data

• Successfully manufactured recombinant tissue kallikrein, overcoming challenges faced by others in the field.

• Recent phase II data in preeclampsia showed significant blood pressure reductions and no placental transfer of DM199.

• Drug demonstrated a 25 mmHg drop in systolic and 13 mmHg in diastolic blood pressure, with a 13% reduction in pulsatility index, indicating improved placental perfusion.

• Safety profile was favorable, with no increase in fetal heart rates and no DM199 detected in cord blood.

• Early evidence suggests potential for disease modification by improving endothelial health and uterine artery dilation.

Market opportunity and unmet need

• Preeclampsia represents a $5+ billion market in the U.S. with 180,000–250,000 cases annually; focus is on the 30,000 early-onset cases before 34 weeks gestation.

• Current treatments are limited, often only delaying delivery by about a week, and many antihypertensives are contraindicated in pregnancy.

• Every additional day of gestation can significantly reduce neonatal mortality and long-term complications.

• Orphan-like pricing is anticipated due to the high unmet need and cost savings from reduced NICU stays and long-term care.

Mechanism of action and differentiation

• DM199 is a recombinant tissue kallikrein, distinct from plasma kallikrein, and does not interact with the fibrinolytic or complement systems.

• The drug increases blood flow and oxygenation to the placenta, potentially addressing the root cause of preeclampsia.

• Similar proteins are used in Asia for stroke and hypertension, but DM199 is a recombinant, purified form.